By Davit Kirakosyan
Raymond James initiated coverage on Xenon Pharmaceuticals (NASDAQ:XENE) with an Outperform rating and a price target of $52.00. Shares were up more than 2% today. Given epilepsy data are highly reproducible, the analysts see very little risk to success for XEN1101 in its lead focal onset seizure (FOS) indication following the robust Ph 2 data generated late last year. According to the analysts, FOS represents a more than $1 billion opportunity at peak, meaning the remaining upside potential is significant at the company’s current approximately $1.6 billion EV.
Credit Suisse initiated coverage on T. Rowe Price Group Inc (NASDAQ:TROW) with an Underperform rating and a price target of $70.00.
UBS initiated coverage on ProKidney Corp (NASDAQ:PROK) with a Buy rating and a price target of $18.00.
Jefferies assumed coverage on Walmart (NYSE:WMT) with a Buy rating and a price target of $165.00, noting that the company remains the value leader and an outsized trade-down beneficiary.
Baird initiated coverage on Splunk (NASDAQ:SPLK) with an Outperform rating and a price target of $130.00. Shares were up more than 2% today.
Credit Suisse initiated coverage on KKR & Co Inc (NYSE:KKR_pc) with a Neutral rating and a price target of $48.00.
Jefferies initiated coverage on Range Resources (NYSE:RRC) with a Hold rating and a price target of $31.00.
Want to get this news first? Upgrade to InvestingPro for real-time market coverage.